Category - News

Developments

Omeq Medical receives FDA approval for epidural injections smart device

Closely-held Omeq Medical, a portfolio company of Israel’s The Trendlines Group (SGX:42T;TCQX:TRNLY), received regulatory clearance from the FDA for its EpiFinder device, which assists physicians to accurately position...

May 9, 2023

Developments

Acasti submits Phase 3 safety protocol; implements strategic realignment

Acasti Pharma (NASDAQ:ACST) submitted to the FDA the full protocol of its GTX-104 for a Phase 3 safety study of a rare disease, aneurysmal subarachnoid hemorrhage, and implementation of a strategic realignment plan to...

May 8, 2023

Developments

Visus posts positive Phase 3 results in presbyopia

Visus Therapeutics reported that the BRIO-I Phase 3 clinical trial met its primary and secondary endpoints, evaluating the safety and efficacy of BRIMOCHOL PF, a preservative-free ophthalmic solution for the treatment...

May 5, 2023

Developments

FibroGen flunks Phase 3 anemia study

FibroGen’s (NASDAQ:FGEN) Phase 3 MATTERHORN study of roxadustat for treatment of anemia in patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint. The...

May 5, 2023

Developments

MindBio Therapeutics lists on CSE

MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) has listed its common shares on the Canadian Securities Exchange under the ticker symbol, MBIO. MindBio is the only company in the world to have clinical trials approved...

May 5, 2023

Developments

SAB presents positive Phase 1, 2a data in influenza

SAB Biotherapeutics (NASDAQ:SABS) presented positive safety and efficacy data from Phase 1 and 2a clinical trials of its influenza immunotherapy, SAB-176, at the AVG conference, which is hosted by the International...

May 4, 2023

Developments

Immunic posts positive Phase 1b results in celiac disease

Immunic (NASDAQ:IMUX) announced positive results from the part C portion of its Phase 1 clinical trial of IMU-856 in patients with celiac disease. The company believes that this data set provides initial clinical proof...

May 4, 2023

Developments

Magenta, Dianthus in merger agreement

Magenta Therapeutics (NASDAQ:MGTA) and closely-held Dianthus Therapeutics entered into a definitive merger agreement to combine the companies in an all-stock transaction that is expected to close in the third quarter of...

May 3, 2023

Executive Moves

PharmaJet names Nathalie Landry as CSO

PharmaJet appointed Nathalie Landry as chief scientific officer to provide strategic leadership and ensure the company’s clinical and scientific programs align with its global commercial expansion. PharmaJet’s pipeline...

May 2, 2023

Developments

NeuroSense posts positive preliminary PD biomarker data

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive preliminary results from a novel biomarker study conducted to evaluate the potential of its combination platform therapy for the treatment of Parkinson’s...

May 2, 2023

Category - News

Subscribe